Free Trial

Odyssey Therapeutics (ODTX) 10K Form and Latest SEC Filings 2026

$16.93 -0.03 (-0.18%)
As of 06/2/2026 04:00 PM Eastern

Latest Odyssey Therapeutics SEC Filings & Recent Activity

Odyssey Therapeutics (NASDAQ:ODTX) has submitted 49+ documents to the U.S. Securities and Exchange Commission (SEC) since 2022. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form SCHEDULE 13G submitted on May 18, 2026.

Form 4
Odyssey Therapeutics, Inc. Reports Ownership Change on May. 13, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

Odyssey Therapeutics SEC Filing History

Browse Odyssey Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/18/2026 7:20 PM
Lightspeed Venture Partners XV-B (0) Ignite
Odyssey Therapeutics (1882782) Subject
Form SCHEDULE 13G
05/18/2026 5:29 PM
Odyssey Therapeutics (1882782) Subject
SR ONE CAPITAL MANAGEMENT, LLC (1853723) Filed by
Form SCHEDULE 13D
05/18/2026 3:06 PM
Odyssey Therapeutics (1882782) Subject
TPG GP A, LLC (1903793) Filed by
Form SCHEDULE 13D
05/15/2026 1:58 PM
Jeito II S.L.P. (2134396) Filed by
Odyssey Therapeutics (1882782) Subject
Form SCHEDULE 13D
05/13/2026 4:10 PM
COULTER JAMES G (1099776) Reporting
Odyssey Therapeutics (1882782) Issuer
TPG GP A, LLC (1903793) Reporting
WINKELRIED JON (1366946) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 4:37 PM
Dimension Capital II, L.P. (2040933) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 4:36 PM
Dimension Capital II, L.P. (2040933) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/11/2026 8:11 PM
George Simeon (1595117) Reporting
Odyssey Therapeutics (1882782) Issuer
SR ONE CAPITAL MANAGEMENT, LLC (1853723) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:30 PM
Odyssey Therapeutics (1882782) Issuer
Todd Collin M (2050088) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:30 PM
Odyssey Therapeutics (1882782) Issuer
Opipari Anthony W. (2131341) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:30 PM
Glick Gary D (2051249) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:30 PM
Odyssey Therapeutics (1882782) Issuer
Walbert Timothy P (1349376) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:30 PM
Dales Natalie (2130322) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:30 PM
Odyssey Therapeutics (1882782) Issuer
Tatsis Ourania (1789815) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:30 PM
Chu Shelley (1895958) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:30 PM
Odegard Valerie (1832432) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:30 PM
Odyssey Therapeutics (1882782) Issuer
SMITH IAN F (1197032) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:30 PM
Li Nan (0) LN
Odyssey Therapeutics (1882782) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:32 PM
Haas Jason (1883821) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:35 PM
LEIDEN JEFFREY M (1242825) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2026 3:45 PM
Odyssey Therapeutics (1882782) Filer
Form 424B4
05/07/2026 11:15 PM
Odyssey Therapeutics (1882782) Filer
Form EFFECT
05/07/2026 8:39 PM
Odyssey Therapeutics (1882782) Issuer
Tatsis Ourania (1789815) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:40 PM
Odegard Valerie (1832432) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:45 PM
Odyssey Therapeutics (1882782) Issuer
Walbert Timothy P (1349376) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:23 PM
COULTER JAMES G (1099776) Reporting
Odyssey Therapeutics (1882782) Issuer
TPG GP A, LLC (1903793) Reporting
WINKELRIED JON (1366946) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:23 PM
Odyssey Therapeutics (1882782) Issuer
SMITH IAN F (1197032) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:23 PM
Odyssey Therapeutics (1882782) Issuer
Todd Collin M (2050088) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:27 PM
Glick Gary D (2051249) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:28 PM
George Simeon (1595117) Reporting
Odyssey Therapeutics (1882782) Issuer
SR ONE CAPITAL MANAGEMENT, LLC (1853723) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:28 PM
LEIDEN JEFFREY M (1242825) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:30 PM
Li Nan (0) LN
Odyssey Therapeutics (1882782) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:31 PM
Odyssey Therapeutics (1882782) Issuer
Siegel Jolie (1768223) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:31 PM
Odyssey Therapeutics (1882782) Issuer
Opipari Anthony W. (2131341) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:34 PM
Dales Natalie (2130322) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:34 PM
Chu Shelley (1895958) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:17 PM
Odyssey Therapeutics (1882782) Issuer
Pavletic Aranicki Ksenija (2131727) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:21 PM
Hill Paulina (1710965) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:22 PM
NG CAROLYN (1777346) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 8:22 PM
Haas Jason (1883821) Reporting
Odyssey Therapeutics (1882782) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/07/2026 7:28 PM
Odyssey Therapeutics (1882782) Filer
Form S-1MEF
Goldman Sachs just told you what to buy (most people missed it) (Ad)

Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.tc pixel

See the stock positioned to solve AI's biggest power crisis
05/07/2026 2:12 PM
Odyssey Therapeutics (1882782) Filer
Form CERT
05/05/2026 12:00 PM
Odyssey Therapeutics (1882782) Filer
Form 8-A12B
05/04/2026 5:05 AM
Odyssey Therapeutics (1882782) Filer
Form S-1/A
04/17/2026 3:05 PM
Odyssey Therapeutics (1882782) Filer
Form S-1
Registration statement under Securities Act of 1933  
12/04/2025 1:51 PM
Odyssey Therapeutics (1882782) Filer
Form D
Notice of Exempt Offering of Securities 
(Data available from 1/1/2016 forward)

Odyssey Therapeutics SEC Filings - Frequently Asked Questions

Odyssey Therapeutics (ODTX) has submitted 49+ filings to the SEC since 2022. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form SCHEDULE 13G submitted on May 18, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:ODTX) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners